November 3, 2003
Source: Non-Invasive Monitoring Systems Inc.
North Bay Village, Fla.
Non-Invasive Monitoring Systems Inc. today announced the results of two studies presented in Orlando on October 25-30, at the annual meeting of the American College of Chest Physicians. Dr. Sackner, Emeritus Director of Medical Services at Mt. Sinai Medical Center and Chairman, Board of Directors NIMS, and Dr Adams, Chief of Neonatology, Mt. Sinai Medical Center, Miami Beach conducted these investigations.
They reported that 45 minutes of AT101 application in 14 healthy subjects and 40 patients suffering from a variety of illnesses released nitric oxide in all trials. Its importance is reflected by the award of the Nobel Prize in Medicine in 1998 for discoveries concerning "nitric oxide as a signaling molecule in the cardiovascular system." Nitric oxide levels in the blood are increased naturally in the body during active exercise and accounts for several of its beneficial effects including prevention of arteriosclerosis.
Drs. Sackner and Adams said that "nitric oxide is beneficial to the body because it opens blood vessels more widely and suppresses inflammation in a way similar to cortisone products without the harmful side effects of these drugs." Ten to 15 daily AT101 applications of AT101 passive exercise device were administered to 25 patients with chronic inflammatory diseases and a quality of life questionnaire provided before and after the trial. These diseases included osteoarthritis, Parkinson's disease, multiple sclerosis, neuropathy, fibromyalgia, asthma, chronic fatigue syndrome, restless legs syndrome, chronic venous insufficiency, and coronary artery disease. There were statistically significant improvements in vitality, body pain and role physical following the application of the AT101 program. "These benefits suggest that the body's release of nitric oxide with the AT101 passive exercise device might be beneficial to a large number of other diseases which have as their basis chronic inflammation," added Drs Sackner and Adams.
In another paper, Drs Sackner and Adams reported that the magnitude of nitric oxide induced vasodilator effect attendant with AT101 application was similar to low intensity cycling exercise. They also tested a motorized bicycle that passively moved the legs and did not find that this device released nitric oxide. Drs Sackner and Adams stated, "this study indicates that passive exercise devices differ in their similarity to active exercise in terms of nitric oxide release and that the AT101 provides an aid to the circulation."
The AT101 is a comfortable platform, mounted on a hospital-like patient gurney, that moves the body repetitively in a back and forth motion from head to foot, similar to the movement used to comfort a child in a baby carriage but at a more rapid pace. Dr. Sackner describes the AT101 as the passive equivalent of jogging or galloping on a horse.
Acceleration Therapeutics, a wholly owned division of NIMS, markets the AT101 worldwide. The AT101 is listed with the FDA as a Class I exempt device intended as an aid to improve the circulation and joint mobility. It also has ISO 9001 certification.
The AT101 is the latest medical innovation by NIMS, which develops products that improve the quality of patients' lives without the need for drugs or surgery. Dr. Sackner, who has invented five commercially successful medical devices and has 30 patents, is Past Professor of Medicine at the University of Miami at Mt. Sinai and Emeritus Director of Medical Services at Mt. Sinai Medical Center. He is a past President of the American Thoracic Society, past Chairman of the Pulmonary Disease Subspecialty Board and a past Member of the American Board of Internal Medicine.
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995: The Statements which are not historical facts contained in
this press release are forward-looking statements that involve certain
risks and uncertainties including but not limited to risks associated with
the uncertainty of future financial results, additional financing requirements,
development of new products, government approval processes, the impact
of competitive products or pricing, technological changes, the effect of
economic conditions and other uncertainties detailed in the Company's filings
with the Securities and Exchange Commission.
Copyright © 2003, Business Wire